Skip to Main Content

Mirati Therapeutics said Monday that its KRAS-targeting cancer drug called adagrasib combined with another immunotherapy was well-tolerated by patients with lung cancer — avoiding the serious liver side effects and treatment discontinuations that have stalled similar efforts by Amgen.

The new safety data are a boost to Mirati’s efforts to expand the number of patients with KRAS-mutated lung cancer who might benefit from adagrasib — and help the drug grow into a commercial blockbuster.


In the mid-stage study reported Monday, moderate, or grade 3, increases in two liver enzymes — markers for liver toxicity — were reported in 8% and 9% of the 75 patients with newly diagnosed lung cancer evaluable for safety. The patients were treated with adagrasib plus Keytruda, the checkpoint inhibitor immunotherapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.